The Necrotic Signal Induced by Mycophenolic Acid Overcomes Apoptosis-Resistance in Tumor Cells by Guidicelli, Gwendaline et al.
The Necrotic Signal Induced by Mycophenolic Acid
Overcomes Apoptosis-Resistance in Tumor Cells
Gwendaline Guidicelli
1,2,3,4., Benjamin Chaigne-Delalande
1,2,3., Marie-Sarah Dilhuydy
5, Benoı ˆt
Pinson
2,6, Walid Mahfouf
1,2,3, Jean-Max Pasquet
2,3,7, Franc ¸ois-Xavier Mahon
2,3,7, Philippe Pourquier
2,3,8,
Jean-Franc ¸ois Moreau
1,2,3,4, Patrick Legembre
1,2,3*
1CNRS UMR 5164, Bordeaux, France, 2Universite ´ Bordeaux-2, Bordeaux, France, 3IFR-66, Bordeaux, France, 4Centre Hospitalier Universitaire de Bordeaux, Bordeaux,
France, 5Service des maladies du sang, Ho ˆpital du Haut-Le ´ve ˆque, Pessac, France, 6CNRS UMR 5095, Bordeaux, France, 7INSERM U 876, Bordeaux, France, 8INSERM E347,
Institut Bergonie ´, Bordeaux, France
Abstract
Background: The amount of inosine monophosphate dehydrogenase (IMPDH), a pivotal enzyme for the biosynthesis of the
guanosine tri-phosphate (GTP), is frequently increased in tumor cells. The anti-viral agent ribavirin and the
immunosuppressant mycophenolic acid (MPA) are potent inhibitors of IMPDH. We recently showed that IMPDH inhibition
led to a necrotic signal requiring the activation of Cdc42.
Methodology/PrincipalFindings: Herein,westrengthenedthe essential role playedbythis smallGTPaseinthe necroticsignal
by silencing Cdc42 and by the ectopic expression of a constitutive active mutant of Cdc42. Since resistance to apoptosis is an
essential step for the tumorigenesis process, we next examined the effect of the MPA–mediated necrotic signal on different
tumor cells demonstrating various mechanisms of resistance to apoptosis (Bcl2-, HSP70-, Lyn-, BCR-ABL–overexpressing cells).
All tested cells remained sensitive to MPA–mediated necrotic signal. Furthermore, inhibition of IMPDH activity in Chronic
Lymphocytic Leukemia cells was significantly more efficient at eliminating malignant cells than apoptotic inducers.
Conclusions/Significance: These findings indicate that necrosis and apoptosis are split signals that share few if any
common hub of signaling. In addition, the necrotic signaling pathway induced by depletion of the cellular amount of GTP/
GDP would be of great interest to eliminate apoptotic-resistant tumor cells.
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Introduction
An increase rate in malignancies after organ transplantation is
the toll to pay for allograft long-term survival and the post-
transplant lymphoproliferation disorders (PTLD) represent the
major cause of cancer-related mortality in kidney transplant
recipients [1]. Mycophenolate mofetil (MMF) is an immunosup-
pressive agent widely used in transplantation the active compound
of which, mycophenolic acid (MPA), depletes the intracellular pool
of GTP through the inhibition of the inosine monophosphate
dehydrogenase (IMPDH). IMPDH is found frequently over-
expressed in tumor cells, making it an attractive target for the
generation of anti-tumoral agents [2]. Recently it has been
observed a tendency toward a lower risk of malignancy in the
MMF versus non-MMF given transplanted patients [3] and MPA
was endowed with an antitumoral action in an experimental in a in
vivo tumor growth model [4].
Cell death plays an essential role in the homeostasis of tissues
and organs and allows the elimination of infected or transformed
cells. So far, three types of major cell death have been described:
apoptotis (type I), autophagic cell death (type II) and necrosis (type
III) [5]. Resistance to apoptosis occurs during tumorigenesis and
explains tumor relapse following chemotherapeutic treatment. To
evade apoptosis, tumor cells use various mechanisms, a number of
which have not yet been characterized. For instance, chronic
myeloid leukemia (CML) is characterized by the expression of a
chimeric BCR-ABL oncoprotein in hematopoietic precursor cells
[6] which behaves as a potent inhibitor of apoptosis [7]. Cancer
cells from Chronic Lymphocytic Leukemia (CLL) are also
reported to display a common default in apoptosis [8].
Furthermore, 80% to 90% of the low grade follicular non-
Hodgkin lymphomas resist to apoptosis through the over-
expression of Bcl-2 a potent inhibitor of the mitochondrion-
dependent apoptotic signal [9].
Cdc42 is a key factor linking intracellular and extracellular
signals to the organization of the actin cytoskeleton network [10].
This small GTPase belongs to the Rho-GTPase family. Herein, we
demonstrated the pivotal role of Cdc42 to transmit the MPA-
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newly characterized necrotic signal shared common signaling hubs
with various apoptotic pathways by examining the cytotoxic action
of MPA on different tumor cells exhibiting resistance to apoptosis.
Materials and Methods
Ethics statement
All clinical investigation has been conducted according to the
principles expressed in the Declaration of Helsinki. Blood was
sampled from patients diagnosed with B-CLL after written consent
was obtained from each individual. This study was approved by
institutional review board at the Centre Hospitalier Universitaire
de Bordeaux.
Patients
All CLL patients were Binet stage A. Using Ficoll separation
and elimination of monocytes by adherence, the purified B-
lymphocytes (.85% of the isolated cells were CD19
+CD5
+ B
lymphocytes) were maintained in a RPMI medium supplemented
with 8% human serum.
Cells
The lymphoblastoid B-cell lines Dab-1, the leukemic T-cell lines
CEM and Jurkat and the chemotherapy-resistant cells were grown
in RPMI 1640 supplemented with 8% v/v heat-inactivated FCS
and 2 mM L-glutamine at 37uC in a humidified atmosphere
containing 5% CO2. PBLs (peripheral blood lymphocytes) from
healthy donors were isolated by Ficoll gradient centrifugation
exactly as described previously [11]. Doxorubicin-resistant Jurkat
and CEM cells were derived by treatment with stepwise increase in
the concentration of doxorubicin and clones were isolated by the
limiting dilution method. Generation of Bcl-2 over-expressing
Jurkat cells was described elsewhere [12].
Reagents
Guanosine, adenosine, ribavirin, mycophenolic acid, latrunculin
A and cytochalasin D were purchased from Sigma (St Louis, MO,
USA). Soluble CD95L was generated in the laboratory [13].
Nilotinib (AMN-107) was obtained by Dr Mahon F.X. from
Novartis Pharma AG. The anti-Bcl-2 mAb and the anti-CD95
mAb (clone DX2) were purchased from Pharmingen (BD
Biosciences, San Diego, CA, USA). Killer TRAIL was purchased
from Alexis (Coger, France). Isotypic antibody (anti-LIF, clone
1F10) was a home-generated mAb. Secramine A was synthesized
by Dr Xu B. and Hammon G.B. (University of Louisville,
Louisville, USA) and was kindly provided by Dr Kirchhausen T.
(Harvard Medical School, Boston, USA).
Plasmids and transfection
Q61L-Cdc42-GFP and Q61L-Rac1-GFP were obtained from
Dr Fort P. (Montpellier, France). Two small hairpin RNA
(shRNA) targeting Cdc42 were designed (shRNA#35 9-
agactcctttcttgcttgttgg-39 and shRNA#45 9-agtatgtggagtgttctgcact-
39) and cloned into the plasmid pSuppressorNeo (Imgenex, San
diego, CA, USA). A negative control plasmid with a scrambled
sequence was supplied by Imgenex. The pEGFP-Bcl-2 plasmid
was kindly provided by Dr Youle R. (NIH, Bethesda, MD).
Cells (5.10
6 cells in 0.3 ml) were electroporated with 10 mgo f
DNA using a BTX ECM 830 electroporation generator (BTX
Instrument Division, Holliston, MA, USA). Twenty hours later,
living cells were isolated using a Ficoll separation method as
described elsewhere [13].
For transient transfection assay, Jurkat T cells were electropo-
rated with the GFP-fused constitutive active mutants of Cdc42 and
Rac1 alone or the cells were co-transfected with the indicated
shRNA and the pEGFP-N1 vector at a ratio of 3:1 (10 mg of total
DNA). After pulse discharge, the cells were placed in 6 ml of
complete medium and incubated for 20 hours at 37uC. Living cells
were isolated over a Ficoll gradient and then treated or untreated
with MPA for 40 hours.
Western blot analysis
Cells were lysed for 30 minutes at 4uC in lysis buffer (25 mM
HEPES pH 7.4, 1% v/v Triton X-100, 150 mM NaCl,
supplemented with a mix of protease and phosphatase inhibitors
(Sigma)). Protein concentration was determined using the
bicinchoninic acid method (Pierce, Brebie `res, France) according
to the manufacturer’s protocol. Proteins were separated by
electrophoresis using a SDS-PAGE and transferred to a nitrocel-
lulose membrane (Amersham Biosciences, Buckinghamshire, UK).
Immunoblots were performed exactly as previously described [12].
Phalloidin staining
Cells were pre-incubated with the inhibitors of actin polymer-
ization for 30 min at 37uC, then fixed in PBS/2% PFA for
30 minutes, washed and treated for 15 minutes with PBS/5%
FCS to quench aldehyde groups. Cells were permeabilized 5 min
at 4uC using PBS/0.1% Triton X-100 and stained with FITC-
linked phalloidin (Sigma) (1 mg/ml) for 30 min at 4uC. Cells were
washed and the intensity of fluorescence was assessed by flow
cytometry using the CANTO II flow cytometer (BD Biosciences).
Cell death assays
Cell viability was assessed using the metabolic assay MTT, as
previously described [14].
The necrotic morphology was assessed by flow cytometry as
described previously [15]. Briefly flow cytometric parameters, cell
size (FSC) and granule content of the cells (SSC), allowed to define
a window corresponding to the living cells (untreated cells). MPA
treatment revealed a population which harbored a size similar to
living cells but contained more granules. This cell population
remained insensitive to the inhibition of caspases using zVAD-fmk
pre-treatment and corresponded to the necrotic cells [15].
To assess plasma membrane permeability, treated or untreated
cells were incubated for 1 hour with regular medium containing
the membrane-impermeant dye propidium iodide (20 mg/ml) and
then immediately analyzed by flow cytometry.
Measure of the mitochondrial Potential (DYm). Cells were pre-
incubated with DiOC6 (10 nM) for 15 min and then stimulated
with CD95L or MPA. Cell fluorescence was measured by flow
cytometry.
Dosage of intracellular GTP/GDP levels
Cellular extracts were prepared using an ethanol extraction
method. Treated or untreated cells (10610
6 cells) were lysed
(10 mM Hepes pH 7.2, 75% v/v Ethanol) at 80uC for 3 minutes.
The ethanol/Hepes solution was evaporated in a rotavapor
apparatus. The pellet was resuspended in 500 ml water and
guanine-derivatives were separated by HPLC on a CarboPac
PA10 column (250 mm64 mm; Dionex Sunnyvale, CA, USA)
equipped with PA1 guard column. Guanine derivatives were
detected at 260 nm with a PDA100 photodiode array detector
(Dionex) and were quantified by comparison with calibration
curves obtained with guanine-derivative standards.
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Treated cells (10
7) were fixed for 1 hour at 4uC in 1.5% v/v
glutaradehyde (0.1 M phosphate buffer), post-fixed in 1% w/v
osmium tetroxide for 1 hour at 4uC, dehydrated in ethanol and
embedded into a Epon resin mixture. Ultra-thin sections were
double stained using uranyl acetate and lead citrate. Finally,
sections were analyzed using a FEI Tecnai 12Biotwin (FEI,
Hillsboro, OR, USA) transmission electron microscope.
Results
The GTP/GDP-depletion drives a Cdc42 and actin-
dependent necrotic signal
We previously showed that therapeutical doses of MPA and
Ribavirin, two potent inhibitors of the IMPDH led to the
elimination of activated PBLs through a caspase-independent
necrotic signal [15]. Using transmission electron microscopy, we
confirmed that activated PBLs were eliminated mainly by necrotis
(Figure 1).
We recently pointed out that MPA promoted the activity of
Cdc42, which was important to transmit the necrotic signal [15].
To formally prove the involvement of Cdc42 in the necrotic signal,
we tested the effect of a new selective inhibitor termed Secramine
A [16]. Secramine A decreased the proportion of MPA-induced
necrotic cell death in both the B cell line Dab-1 (40 to 50%
inhibition) and in the T cell line Jurkat (40% inhibition) (Figure 2A)
as assessed by the measurements of the cell morphology (flow
cytometry analysis using FSC and SSC parameters, see [15]) or
the plasma membrane permeability (cell entry of propidium
iodide). Since GTPases switch from an active, GTP-bound, to an
inactive, GDP-bound form, by the hydrolysis of GTP, we next
examined the effect of a GTP-locked version of Cdc42
(constitutively active mutant termed Q61L-Cdc42) or of Rac1
(Q61L-Rac1 was taken as control) upon MPA-mediated cell death.
The constitutive active GTPases were fused to GFP (green
fluorescent protein). After transfection, living cells were isolated
and the proportion of cells expressing the chimeric protein (green
cells) was comprised between 30 and 40%. Unlike Q61L-Rac1 or
GFP alone, the expression of the constitutive active mutant of
Cdc42 significantly enhanced the necrotic signal generated by the
addition of MPA (see Figure 2B, upper panel). The increased rate
of cell death was correlated to a significant decrease of the ratio of
green cells among the living cells (Figure 2B, upper panel)
indicating that a constitutive active Cdc42 promoted the necrotic
signal triggered by the addition of MPA. We next examined the
effect of the Cdc42 silencing on the necrotic signal using small
hairpin RNAs (shRNA). Since the small GTPases Rac1 and
Cdc42 share 66.8% of DNA sequence identity, we controlled the
specificity of the designed shRNA towards Cdc42 by comparing its
action on the expression level of both Cdc42 and Rac1. Two
Figure 1. IMPDH inhibition leads to a necrotic morphology. Electron micrographs of activated PBLs. Cells were incubated with MPA (3 mg/mL)
or with ribavirin (100 mg/ml) for 44 hours (Bars=2 mm).
doi:10.1371/journal.pone.0005493.g001
Necrosis Kills Tumor Cells
PLoS ONE | www.plosone.org 3 May 2009 | Volume 4 | Issue 5 | e5493Figure 2. Cdc42 and actin are implicated in the MPA-mediated necrotic signal. (A) Cells were pre-incubated with secramine A (40 mM) or
DMSO for 1 hour and then incubated for 44 hours with MPA. Necrosis was quantified by assessing the loss of the plasma membrane integrity (entry
of propidium iodide) and the cell morphology. (B) Upper panel: Jurkat cells transfected with plasmid encoding Q61L-Cdc42-GFP, Q61L-Rac1-GFP or
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they did not modify the protein expression of Rac1 (Figure 2B,
lower panel, see the inset). The T cell Jurkat was co-transfected
with the shRNA and the GFP encoding plasmids at a molecular
ratio of 3:1 and we followed the fate of the green cells (GFP
positive) upon the addition of MPA. For each condition, green
cells corresponded to 40–60% of the living cells. As shown in
Figure 2B (lower panel), the down-expression of Cdc42 dramat-
ically impaired the MPA-mediated necrotic signal. Additionally,
the silencing of Cdc42 was correlated with an enrichment of the
GFP-expressing cells among the living cells (Figure 2B, lower
panel). Taken together these results established that Cdc42 played
a pivotal function in the transmission of the MPA-mediated
necrotic signal.
By remodeling the actin cytoskeleton, Cdc42 participates in
various cellular processes such as cell motility and cytokinesis [10].
To identify where actin remodeling acts in the molecular ordering
of the MPA-mediated necrotic signal, we investigated the effect of
inhibitors of actin polymerization on an early step (depletion of
GTP and GDP) and a late step (loss of mitochondrial potential
DYm), the latter being considered as an irreversible process in cell
death [5]. As Phalloidin displays a strong affinity for polymerized
actin (F-actin) [17], fluorescent-conjugated phalloidin was used to
monitor by flow cytometry the amount of F-actin in permeabilized
cells. Latrunculin A (LtnA) and cytochalasin D (CytD) are potent
inhibitors of actin polymerization. The pre-incubation of the B-cell
line Dab-1 and the T-cell line Jurkat with non-toxic concentrations
of these chemicals significantly decreased the phalloidin staining
(Figure 2C) confirming that actin polymerization was prevented in
the treated cells. The dramatic decrease of the intracellular pools
of GTP and GDP observed during the inhibition of the IMPDH
(Figure 2D) remained unchanged when actin polymerization was
abrogated either by latrunculin A or cytochalasin D (Figure 2D).
Conversely, the inhibitors of actin polymerization significantly
impaired the drop of DYm induced by MPA in the T cell line
Jurkat and completely abrogated it in the B cell line Dab-1
(Figure 2E). These findings established that the necrotic signal
induced by MPA relied on the remodeling of the actin
cytoskeleton and this cellular process took place downstream the
GTP depletion and upstream the abrogation of mitochondria
functions.
Apoptosis-resistant tumor cell lines remain sensitive to
the necrotic signal
Resistance of the malignant cells to apoptosis is an important
issue in oncology, hence we next investigated whether the newly
characterized necrotic signal remained efficient to eliminate in vitro
and ex vivo tumor cells that harbored different molecular
mechanisms to resist apoptosis.
Doxorubicin, which is commonly used for the treatment of non-
Hodgkin’s lymphomas, induces an apoptotic signal [18]. From the
leukemic T-cell lines Jurkat and CEM, we generated tumor cells
resistant to doxorubicin-mediated apoptosis (Figure 3A and 3C).
The selected clones did not display any modifications of the influx
or efflux of doxorubicin indicating that the expression and the
activity of the ATP-Binding Cassette, subfamily B (ABCB1/MDR-
1) remained unchanged in these cells and therefore could not be
held responsible for drug resistance (data not shown). Doxorubicin
has been described to induce cell death of leukemia cells through
the induction of a CD95L-dependent apoptotic signal [18]. As a
consequence, it was expected that a selected doxorubicin-resistant
CEM clone (CEM
DoxR) was resistant to the apoptotic inducer
CD95L (Figure 3A). This clone expressed a similar amount of
membrane CD95 compared to its respective parental cell line
(Figure 3B). Since the TRAIL-mediated apoptotic signal was also
impaired in this CEM
DoxR (Figure 3A), we concluded that the
default in apoptosis was not caused by a CD95 mutation but
instead, by the modulation of a yet undefined intracellular target.
It is noteworthy that compared to the parental cell line, none of
the isolated Jurkat
DoxR clones exhibited resistance to CD95L (data
not shown) suggesting that these clones displayed a different
mechanism to resist doxorubicin-mediated apoptosis compared to
the one present in the CEM
DoxR cell line. Despite their resistance
to apoptosis, the magnitude of MPA-mediated cell death was not
altered in the CEM
DoxR and Jurkat
DoxR compared to their
respective parental cells (Figure 3A and 3C). The inhibitor of
topoisomerase II etoposide is used for the treatment of refractory
non-Hodgkin lymphomas [19]. Using the etoposide resistant cell
line CEM VM-1 [20], we observed that it displayed a similar
sensitivity to MPA compared to the parental cell line (Figure 3D).
These data suggest that there does not exist any crosstalk between
the necrotic signal triggered by MPA and different molecular
mechanisms developed by cells to resist etoposide or doxorubicin-
induced apoptotic cell death.
Chronic myeloid leukemia (CML) cells express an oncogene
protein consisting of the gene fusion of BCR (Breakpoint Cluster
Region) and the tyrosine kinase ABL (Abelson), which behaves as a
potent inhibitor of apoptosis [7]. Imatinib and nilotinib, two
tyrosine kinase inhibitors, are used for the treatment of chronic
myeloid leukemia suffering patients. By incubating different
chronic myelogenous leukemia-derived cell lines (K562, AR230,
LAMA84) with imatinib or nilotinib, resistant cells were selected.
To resist cell death induced by the inhibitors of BCR-ABL activity,
these cells promote different molecular mechanisms such as
amplification of the BCR-ABL locus [21], over-expression of the
members of src kinase family [22] or the increase expression of the
anti-apoptotic chaperone protein Hsp70 [23] (Figure 4A). Hsp-70
has been reported as a potent inhibitor of apoptotic signals
induced by lysosomal membrane permeabilization [24], death
receptor signaling and ceramide production [25]. The over-
expression of the kinase Lyn prevents the apoptotic signal
triggered by tyrosine kinase inhibitors [26]. Although these
different molecular mechanisms were very efficient to protect the
CML cells from imatinib (Figure 4B, left panel) and nilotinib-
GFP alone were treated with MPA for 44 hours. The percentage of dead cells (morphologic analysis) and the percentage of GFP-expressing cells
among the living population are shown. Lower panel: Jurkat cells were transfected with the Cdc42-targeting shRNA or control shRNA (Scr) and pEGFP-
N1 at a DNA weight ratio of 3:1. 24 hours after transfection, living cells were isolated by Ficoll gradient and incubated for 44 hours with MPA. Cell
death was assessed by analyzing plasma membrane damage (propidium iodide entry). The inset depicts the expression of Cdc42 and Rac1 in Jurkat
cells untransfected (U) or transfected with scramble shRNA (Scr) or shRNA targeting Cdc42. Western blots were performed using the indicated
antibodies. (C) The B-cell line Dab-1 and the T-cell line Jurkat were treated with Latrunculin (LtnA, 2.5 mM), Cytochalasin D (CytD, 5 mM) or DMSO
(control) for 30 minutes. Cells were then fixed, permeabilized and F-actin was tagged using FITC-labeled phalloidin. The amount of F-actin was
assessed by flow cytometry. (D) Cells were pre-incubated for 30 min with 2.5 mM of LtnA, 5 mM of CytD or DMSO and then treated in presence or not
of MPA (5 mg/ml) for 14 hours. The amount of GTP (upper panel) and GDP (lower panel) was quantified as described in Materials and Methods. (E) Cells
were pre-incubated for 30 min with LtnA (2.5 mM) or CytD (5 mM) and then treated with 5 mg/ml of MPA for the indicated times. DYm was assessed
using DiOC6 staining. Data represent the mean6SD of three independently performed experiments.
doi:10.1371/journal.pone.0005493.g002
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out to be unable to cripple the necrotic signal induced by MPA
(see Figure 4B, right panel).
The anti-apoptotic factor Bcl2 is over-expressed in various non-
Hodgkin lymphomas in which it prevents cell death induced by
numerous apoptotic inducers targeting the mitochondria [27]. We
over-expressed Bcl-2 in the leukemic T-cell line Jurkat and we
analyzed the effect of this potent anti-apoptoticfactor upon the MPA-
mediated necrotic signal. As expected, Bcl2 impinged on the deaths
triggered by both the apoptotic inducers CD95L (extrinsic death
inducer) and staurosporine (intrinsic death inducer), whereas it
remainedinefficienttoaltertheMPA-mediatedcelldeath(Figure4C).
Taken together these findings showed that the necrotic signal
induced by the depletion of GTP/GDP did not share any
common signaling hubs with the array of apoptotic pathways
triggered by various chemotherapeutic agents.
Tumoricid action of MPA towards primary tumor cells
Tumor cells isolated from Chronic Lymphocytic Leukemia
(CLL) patients share the common feature to be resistant to
apoptosis [28]. In addition, the isoform 2 of IMPDH has been
found over-expressed in these tumoral B cells compared to normal
lymphocytes [29]. TNF-Related Apoptosis-Inducing Ligand
(TRAIL) is an apoptotic cytokine that exhibits a cytotoxic action
on leukemic and lymphoma cells either alone or in combination
with chemotherapeutic agents [30]. Similarly to TRAIL, CD95L
belongs to the TNF (tumor necrosis factor) family and is a potent
inducer of apoptosis. To determine whether MPA was able to
achieve an anti-tumoral action on primary tumor cells resistant to
apoptosis, we compared its effect to TRAIL and CD95L on freshly
isolated B-CLL cells.
The concentration of TRAIL used to kill CLL (500 ng/ml) cells
was comprised between the residual and the maximum of the
TRAIL concentration measured in the sera of patients included in
phase Ia and Ib clinical trials [31]. This concentration killed
between 80 and 100% of the lung carcinoma (A427, H2122),
colorectal adenocarcinoma (COLO 205, SW948, DLD-1),
pancreas adenocarcinoma (BxPC3, HPAC) [32]. The concentra-
tion of CD95L (500 ng/ml) applied on the B-CLL cells eliminated
100% of the EBV-transformed lymphoid (SKW 6.4, Dab-1) and
the T leukemia (Jurkat, CEM) cell lines (data not shown).
It is noteworthy that around 30% of the isolated B-CLL cells
underwent spontaneous cell death (see untreated cells in Figure 5).
Quantification of cell death revealed that untreated B-CLL cells
were not significantly sensitive to TRAIL or CD95L (spontaneous
cell death corresponded to 31.168.3 vs 35.664.6 for TRAIL and
38611.2 for CD95L, Figure 5). In contrast these malignant cells
underwent a significant and more potent cell death signal when
incubated with therapeutical dose of MPA (10 mg/ml) (31.168.3
vs 45.668.8). Taken together, these findings ascertained that
primary tumor cells reported to be highly resistant to apoptosis still
remained sensitive to the MPA-mediated necrotic signal.
Figure 3. Apoptosis resistances are bypassed by the MPA–mediated necrotic signal. (A) Parental CEM and doxorubicin-resistant CEM
(CEM
DoxR) were incubated with indicated dose of doxorubicin, CD95L, TRAIL or MPA for 48 hours. Cell death was measured using a MTT assay. (B)
Flow cytometry analysis of the CD95 expression on the doxorubicin-resistant CEM. (C) Parental Jurkat and the selected doxorubicin resistant clones
(Jurkat
DoxR) were incubated for 48 hours with doxorubicin and MPA at the indicated concentrations. MTT assay was performed to quantify cell death.
(D) CEM and the etoposide resistant CEM-VM1 were incubated with the etoposide or MPA for 48 hours and cell death was assessed using MTT assay.
Results shown represent the mean6SD of three independent experiments.
doi:10.1371/journal.pone.0005493.g003
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The cell-depletion of GTP/GDP eliminates cells through a
necrotic signal that is reliant on intact activity of Cdc42 and the
remodeling of actin. We show for the first time that the atypical
and newly characterized necrotic signal triggered by the inhibition
of the IMPDH activity remains unaffected in different tumor cell
lines and in freshly isolated cancer cells for which the apoptotic
signal is crippled.
Resistance to apoptosis is an essential step in the tumorigenesis
process allowing the cell to increase its genetic instability and to
escape from immunosurveillance. Leukemic and lymphoma cells
exhibit the deregulation of a large range of cellular processes
leading to escape the immune system and/or the chemothera-
peutic treatments and thereby to overcome their tumoricidal
action. In accordance with our findings, Dyer and colleagues
argued that numerous tumor cells were resistant to TRAIL-
mediated apoptosis [33] and the same group pointed out that the
combination of TRAIL with histone deacetylase inhibitors was
required to sensitize tumor cells to death [34]. In our hands no
additional pre-treatment was necessary to sensitize CLL cells to
the necrotic effect mediated by therapeutical dose of MPA. These
findings suggest that the use of IMPDH inhibitors alone or in
combination with other chemotherapeutic agents may promote
the elimination of CLL cells. As a consequence, a more
comprehensive knowledge of the necrotic signal mediated by the
depletion of GTP/GDP would be of a great value to disclose new
therapeutic targets with the purpose of eliminating apoptosis
resistant tumors.
Numerous targets have been characterized for Cdc42 and the
human Wiskott–Aldrich syndrome protein (WASP) is an effector
of Cdc42 playing an important function in the remodeling of actin
upon Cdc42 activation. The WASP family includes WASP, N-
WASP (neural WASP), WAVE (WASP verprolin homologous)-1,
WAVE-2 and WAVE-3. Mateo and colleagues showed that the
antibody-mediated aggregation of the CD47 antigen leads to the
induction of a caspase-independent signal responsible of the B-
CLL death [35]. The authors also found that WASP-deficient cells
were unable to transmit the non-apoptotic signal. Using
wiskostatin as a selective inhibitor of N-WASP, we did not
observe any modification of the MPA-mediated necrotic signal
(Chaigne-Delalande B. and Legembre P., unpublished data)
indicating that N-WASP was probably not the link between
Cdc42 and actin polymerization. In the context of the MPA-
mediated necrotic signal, it is conceivable that the actin
remodeling occurs independently of WASP [10], even so we can
not rule out that other members of the WASP family are involved
upon the activation of Cdc42.
Atypical necrotic or necrotic-like signals have been recently
described. However, whereas high doses of CD95L drove a
necrotic signal relying on the expression of RIP and FADD [36],
the caspase-independent signaling pathway induced by the insulin-
like growth factor I receptor stimulation occurred through the
activation of c-Jun N-terminal kinase (JNK) [37]. We previously
showed that RIP and FADD deficient cells responded to MPA
identically to the parental cells and inhibition of the JNK activity
did not impinge on the cell death signal mediated by the IMPDH
inhibition [15]. Furthermore, accumulation of the polyADP ribose
polymers, the product of the enzyme PARP-1 (poly(ADP ribose)
polymerase) has been reported as an inducer of necrosis upon
incubation with the alkylating agent N-methyl-N’-nitro-N-nitro-
soguanidine (MNNG) [38]. In fact MNNG induced a necrotic
signal through the release from the mitochondria of the Apoptosis-
Inducing Factor (AIF), which played an essential role in the phase
I chromatin condensation [39]. Analysis by electron microscopy
did not reveal phase I chromatin condensation in necrotic cells
dying upon MPA treatment. Furthermore, PARP-1 was found
inactivated by cleavage upon the GTP depletion (Chaigne-
Delalande B. and Legembre P., unpublished data). These findings
support that similarly to apoptosis, necrosis has to be considered as
a programmed signal, which occurs through different routes
depending on the initial inducer. Characterization of these
Figure 5. MPA treatment efficiently kills B-CLL cells. Leukemic B-
cells isolated from CLL patients (n=14) were treated with either the
apoptotic inducers TRAIL (500 ng/ml) or CD95L (500 ng/ml) or with
MPA (10 mg/ml) for 72 hours. Then total cell death was quantified using
the metabolic assay MTT (total cell death). Statistical analysis was
performed using a non-parametric Mann-Whitney two sample ranksum
test (n=14). N.S means non-significant and ** P#0.01.
doi:10.1371/journal.pone.0005493.g005
Figure 4. MPA mediates necrosis in malignant cells resistant to apoptosis. (A) Molecular characterization of the imatinib and nilotinib-
resistant CML cell lines. MDR: multidrug-resistance related protein. (2) indicates an expression level similar to the untreated cells, (+) refers to the
ectopic expression of BCR-Abl and (+++) indicates the over-expression of the indicated protein. (B) Imatinib or nilotinib-resistant CML cells were
incubated with the indicated concentrations of imatinib (left panel), nilotinib (middle panel) or MPA (right panel) for 48 hours. Cell death was
measured by MTT assay. (C) Expression of Bcl2 (endogenous and GFP-Bcl2) was assessed in GFP- and GFP-Bcl2-expressing clones by immunoblot. The
indicated cells were incubated for 24 hours with soluble CD95L, staurosporine or MPA for 48 hours. Total cell death was measured by MTT.
doi:10.1371/journal.pone.0005493.g004
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PLoS ONE | www.plosone.org 8 May 2009 | Volume 4 | Issue 5 | e5493signaling pathways will be of great interest to develop new
generation of anti-cancer agent that alone or in combination with
an apoptotic inducer could delay or even prevent tumor relapse
during chemotherapy and hence will have impact on medical
treatments. In this regards, the low toxicity of MPA has already
been proven in a phase I trial for the treatment of multiple
myeloma [40].
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